194 related articles for article (PubMed ID: 33755971)
21. Design, Synthesis, And Evaluation Of Cyanopyridines As Anti-Colorectal Cancer Agents Via Inhibiting STAT3 Pathway.
Xu L; Shi L; Qiu S; Chen S; Lin M; Xiang Y; Zhao C; Zhu J; Shen L; Zuo Z
Drug Des Devel Ther; 2019; 13():3369-3381. PubMed ID: 31576111
[TBL] [Abstract][Full Text] [Related]
22. A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway.
Noori S; Nourbakhsh M; Farzaneh S; Zarghi A
Anticancer Agents Med Chem; 2020; 20(18):2285-2292. PubMed ID: 32767949
[TBL] [Abstract][Full Text] [Related]
23. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells.
Xiong H; Zhang ZG; Tian XQ; Sun DF; Liang QC; Zhang YJ; Lu R; Chen YX; Fang JY
Neoplasia; 2008 Mar; 10(3):287-97. PubMed ID: 18320073
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer.
Liu C; Pan Z; Chen Q; Chen Z; Liu W; Wu L; Jiang M; Lin W; Zhang Y; Lin W; Zhou R; Zhao L
J Exp Clin Cancer Res; 2021 Sep; 40(1):297. PubMed ID: 34551797
[TBL] [Abstract][Full Text] [Related]
26. The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade.
Liu B; Liu Q; Pan S; Huang Y; Qi Y; Li S; Xiao Y; Jia L
J Exp Clin Cancer Res; 2019 Nov; 38(1):455. PubMed ID: 31694696
[TBL] [Abstract][Full Text] [Related]
27. LL1, a novel and highly selective STAT3 inhibitor, displays anti-colorectal cancer activities in vitro and in vivo.
Liu Z; Wang H; Guan L; Lai C; Yu W; Lai M
Br J Pharmacol; 2020 Jan; 177(2):298-313. PubMed ID: 31499589
[TBL] [Abstract][Full Text] [Related]
28. AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Wang SW; Hu J; Guo QH; Zhao Y; Cheng JJ; Zhang DS; Fei Q; Li J; Sun YM
Oncol Rep; 2014 Nov; 32(5):1991-8. PubMed ID: 25216185
[TBL] [Abstract][Full Text] [Related]
29. A novel small molecular STAT3 inhibitor, 5Br-6b, induces apoptosis and inhibits migration in colorectal cancer cells.
Liu Z; Wang H; Guan L; Chen S; Lai M
Anticancer Drugs; 2018 Jun; 29(5):402-410. PubMed ID: 29438179
[TBL] [Abstract][Full Text] [Related]
30. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
[TBL] [Abstract][Full Text] [Related]
31. Ginsenoside 20(S)-Rh2 exerts anti-cancer activity through targeting IL-6-induced JAK2/STAT3 pathway in human colorectal cancer cells.
Han S; Jeong AJ; Yang H; Bin Kang K; Lee H; Yi EH; Kim BH; Cho CH; Chung JW; Sung SH; Ye SK
J Ethnopharmacol; 2016 Dec; 194():83-90. PubMed ID: 27566200
[TBL] [Abstract][Full Text] [Related]
32. LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis.
Wang H; Liu Z; Guan L; Li J; Chen S; Yu W; Lai M
Pharmacol Res; 2020 Mar; 153():104661. PubMed ID: 31982491
[TBL] [Abstract][Full Text] [Related]
33. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
[TBL] [Abstract][Full Text] [Related]
34. Phlorizin from sweet tea inhibits the progress of esophageal cancer by antagonizing the JAK2/STAT3 signaling pathway.
Jia Z; Xie Y; Wu H; Wang Z; Li A; Li Z; Yang Z; Zhang Z; Xing Z; Zhang X
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34036398
[TBL] [Abstract][Full Text] [Related]
35. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
36. Anlotinib exerts anti-cancer efficiency on lung cancer stem cells in vitro and in vivo through reducing NF-κB activity.
Li Z; Tian J; Du L; Gao Y; Wang Y; You F; Wang L
J Cell Mol Med; 2021 Jun; 25(12):5547-5559. PubMed ID: 33955683
[TBL] [Abstract][Full Text] [Related]
37. Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway.
Xu Z; Wu D; Fu D; Tang C; Ge J; Zhang Z; Zhou W
Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):199-203. PubMed ID: 33040836
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
[TBL] [Abstract][Full Text] [Related]
39. Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway.
Huang L; Huang Z; Lin W; Wang L; Zhu X; Chen X; Yang S; Lv C
Int J Oncol; 2019 Jun; 54(6):1969-1980. PubMed ID: 31081055
[TBL] [Abstract][Full Text] [Related]
40. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Liu Y; Wang L; Wu Y; Lv C; Li X; Cao X; Yang M; Feng D; Luo Z
Toxicology; 2013 Feb; 304():120-31. PubMed ID: 23313376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
